Core Insights - The presentation focuses on pivotal updates regarding the MissionEB Phase III clinical trial and the impact of CORDStrom on Recessive Dystrophic Epidermolysis Bullosa (RDEB) [1] Group 1: Company Overview - David Moss serves as the President, CEO, Treasurer, Secretary, and Director of INmune Bio, highlighting the company's leadership structure [1] - The event is being recorded and will be available on the company's YouTube channel later, indicating a commitment to transparency and communication with stakeholders [2] Group 2: Key Personnel - Dr. Mark Lowdell is introduced as the inventor of CORDStrom and a pioneer in cellular therapy, emphasizing his significant contributions to the development of advanced medicinal products [3] - Dr. Anna Martinez is the clinical lead for the MissionEB trial and a leading expert in the field of Epidermolysis Bullosa, showcasing the expertise driving the clinical program [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. between September 24, 2025, and October 31, 2025, about the upcoming lead plaintiff deadline on April 13, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought uniQure shares during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3]. - To serve as lead plaintiff, individuals must file with the court by April 13, 2026, acting on behalf of other class members [3]. Group 2: Case Background - The lawsuit alleges that uniQure misrepresented and/or failed to disclose critical information regarding its Pivotal Study for a drug candidate aimed at Huntington's Disease, including FDA approval status and the potential delay in its Biologics License Application (BLA) timeline [5]. - The defendants allegedly downplayed the likelihood of needing additional studies, which led to misleading statements about uniQure's business and prospects [5]. - The lawsuit claims that when the true details became known, investors suffered damages [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4].

Company Overview - Generate Biomedicines has successfully raised $400 million through its U.S. initial public offering (IPO) by pricing shares at $16 each [1]. Financial Highlights - The IPO raised a total of $400 million, indicating strong investor interest in the company's drug development capabilities [1].

Core Insights - OPKO Health reported a revenue of $148.5 million for the quarter ended December 2025, reflecting a decline of 19.1% year-over-year, but exceeded the Zacks Consensus Estimate by 7.56% [1] - The company's EPS was -$0.04, a decrease from $0.01 in the same quarter last year, but surpassed the consensus estimate of -$0.07 by 39.39% [1] Revenue Breakdown - Revenue from services was $71.1 million, slightly below the average estimate of $72.37 million, marking a year-over-year decline of 31% [4] - Revenue from the transfer of intellectual property and other sources was $33.7 million, exceeding the average estimate of $24.39 million, with a year-over-year decrease of 21.8% [4] - Revenue from products reached $43.7 million, surpassing the estimated $41.31 million, and showed a year-over-year increase of 16.8% [4] Stock Performance - OPKO Health's shares have returned -7.8% over the past month, contrasting with a +0.6% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Viewpoint - Generate Biomedicines, Inc. has announced the pricing of its initial public offering (IPO) at $16.00 per share, aiming to raise gross proceeds of $400 million before expenses [1] Group 1: IPO Details - The company is offering 25,000,000 shares of common stock in the IPO [1] - Underwriters have a 30-day option to purchase an additional 3,750,000 shares at the IPO price [1] - Trading on the Nasdaq Global Select Market is expected to commence on February 27, 2026, under the ticker symbol "GENB" [1] Group 2: Financial Management - Goldman Sachs & Co. LLC and Morgan Stanley are serving as joint lead book-running managers for the offering [1] - Other book-running managers include Piper Sandler, Guggenheim Securities, and Cantor [1] Group 3: Regulatory Information - A registration statement for the securities was filed and declared effective by the U.S. Securities and Exchange Commission on February 26, 2026 [1] - The offering is being conducted solely through a prospectus [1]

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended December 31, 2025 (H1 FY2026). FINANCIAL HIGHLIGHTS FOR H1 FY20261 Performance driven by successful commercial launch of Ryoncil® Total revenue of US$51.3 million (A$78.3 million),2 up from US$3.2 million.Successful U.S. commercial launch of Ryoncil® (remestemcel-L-rknd) ...

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive (the “Class Period”), of the important April 13, 2026 lead plaintiff deadline. SO WHAT: If you purchased uniQure ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHA ...

"we,†or the "Company†) today announced that it will participate in three upcoming investor conferences during March of this year. Members of the Summit leadership team will participate in individual investor meetings along with some fireside chats at the following conferences: TD Cowen's 46th Annual Health Care Conference in Boston on Monday, March 2, 2026 Fireside chat 2:30pm ET Jefferies Conference in Miami on Tuesday. MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit,†...

PayPal Holdings, Inc. (NASDAQ:PYPL) - The class action lawsuit alleges that PayPal misled investors regarding its revenue outlook and growth potential during the class period from February 25, 2025, to February 2, 2026 [6] - PayPal's fourth quarter and full fiscal year 2025 results, announced on February 3, 2026, revealed disappointing earnings and a withdrawal of its 2027 financial targets, leading to a stock price drop of over 20% [6] - The lawsuit claims that the company's optimistic growth plans were unrealistic and that the management failed to provide clear direction, contributing to operational issues [6] REGENXBIO Inc. (NASDAQ:RGNX) - The class action lawsuit involves allegations that REGENXBIO provided misleading information about its gene therapy product candidate RGX-111 during the class period from February 9, 2022, to January 27, 2026 [6] - On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on RGX-111 due to the discovery of an intraventricular CNS tumor in a trial participant, resulting in a 17.8% decline in stock price from $13.41 to $11.01 in one day [6] - The lawsuit claims that the company made overly positive assertions about RGX-111's trial success while concealing material adverse facts regarding its efficacy and safety [6]

Financial Data and Key Metrics Changes - Teknova achieved a top-line revenue growth of 7% in 2025 compared to 2024, with Q4 revenue increasing by 8% to $10.0 million from $9.3 million in Q4 2024 [5][15][16] - Full year revenue for 2025 reached $45 million, up from $37.7 million in 2024 [15][16] - Free cash outflow improved from $13.5 million in 2024 to $9.8 million in 2025, which was better than the guidance of less than $12 million [15][30] Business Line Data and Key Metrics Changes - Lab Essentials revenue for 2025 was $31.0 million, a 7% increase from $28.9 million in 2024, with Q4 revenue remaining stable at $6.8 million [16][17] - Clinical Solutions revenue grew by 47% in Q4 2025 to $2.7 million from $1.9 million in Q4 2024, and for the full year, it increased by 8% to $7.7 million from $7.1 million in 2024 [18][19] - The number of Clinical Solutions customers increased from 48 in 2024 to 60 in 2025, while average revenue per customer decreased by 14% to $128,000 [18][19] Market Data and Key Metrics Changes - The company reported a 25% increase in the number of customers actively buying clinical products, reaching 60 customers [5][6] - Teknova supports at least 70 therapies, with 5 in phase II or later and 12 in phase I, indicating a growth in later-stage therapies [6][7][50] Company Strategy and Development Direction - Teknova aims to become a critical supplier of GMP-grade reagents and expand its presence in high-growth market segments like sequencing and cancer screening [6][9] - The company plans to invest approximately $2 million annually in commercial capabilities to accelerate revenue growth, particularly in emerging segments [10][11] - Teknova expects to achieve adjusted EBITDA positivity by the end of 2027, with a revenue target of $52 million to $57 million [28][29] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term outlook for end markets, citing an uptick in biotech funding and potential FDA approvals for therapies in 2027 [11][12][33] - The company anticipates that increased biotech funding will positively impact revenue, particularly in custom biopharma products [40][46] - Management highlighted the importance of maintaining a strong cost structure while preparing for growth investments [27][30] Other Important Information - Gross margin improved to 33.2% for the full year 2025, up from 19.2% in 2024, driven by higher revenue and manufacturing efficiency [20][21] - Operating expenses decreased to $30.4 million in 2025 from $33.4 million in 2024, reflecting cost-cutting measures [22][23] Q&A Session Summary Question: Growth drivers in emerging segments - Management discussed the potential of sequencing, spatial genomics, and cancer screening as growth drivers, emphasizing the need for commercial investment to enhance customer relationships and brand awareness [35][36] Question: Revenue segments affected by biotech funding - Management indicated that custom biopharma products are most affected by biotech funding changes, historically representing about 25% of revenue [39] Question: Adjusted EBITDA target for 2027 - Management clarified that achieving positive adjusted EBITDA by the end of 2027 requires reaching a run rate of approximately $13 million to $14 million per quarter [43][45] Question: RUO to GMP customer transition - Management confirmed supporting 60 clinical customers and highlighted the significant revenue increase expected as therapies progress through clinical phases [49][50] Question: Average revenue ramp-up time for new customers - Management noted that the ramp-up time is therapy-dependent, with clinical trials potentially taking several years, but expressed optimism about increasing average revenue as therapies advance [54][56] Question: Impact of FDA guidance on drug development timeframes - Management acknowledged that shorter drug development timelines could positively impact business, especially as more therapies reach commercialization [58][61]